VBIO: Pentagon Completes Protocol
Valion Bio announces the Pentagon's Armed Forces Radiobiology Research Institute and National Institute of Allergy and Infectious Diseases completed the design of a survival efficacy protocol to evaluate Entolimod for treating Gastrointestinal Acute Radiation Syndrome
S. House Armed Services Committee's direction to the DoW to develop a resources and fielding plan for prioritizing radiation/nuclear countermeasures that, like Entolimod, are both prophylactic (pre-exposure) and therapeutic (post-exposure). S. S.
government emergency preparedness requirements. 1,2,3 Entolimod is a recombinant deletion variant of Salmonella FliC flagellin engineered to activate TLR5 selectively. Upon engagement, Entolimod triggers specific pathways that ultimately promote multi-tissue cytoprotection and inhibit apoptosis in radiosensitive hematopoietic and gastrointestinal tissues. 5% of bone marrow (one hind leg and tail) from a lethal radiation dose, the study will isolate GI pathophysiology from overwhelming hematopoietic failure — creating a cleaner efficacy signal for a mechanism targeting intestinal epithelial recovery and immune restoration.
Valion Bio CEO, Michael Handley, said, "The AFRRI protocol finalization represents a key inflection point for Entolimod as a radiation/nuclear countermeasure and for Valion as a company. We are now positioned to generate the high-quality non-clinical efficacy data that the FDA and the government require to support future licensure under the Animal Rule. 2%. North America, where government stockpiling and biodefense spending concentrate, accounts for 46% of market revenue.